Zydus Lifesciences Ltd 2022 AR2
The report highlights Zydus Lifesciences Limited's transition from a conventional pharmaceutical company to an innovation-driven life sciences organization in FY22. Key achievements include the launch of Oxemia (Desidustat) in India and the emergency use approval of ZyCov-D, the world's first plasmid DNA vaccine for COVID-19. The company achieved net debt-free status, supported by the divestment of its India-centric animal health business. Additionally, the company expanded its digital footprint across manufacturing, supply chain, and R&D, while continuing its extensive CSR programs through the Zydus Medical College and Hospital in Dahod.
Company: Zydus Lifesciences Ltd
Sector: Health Care
Country: India
Year: 2022
Type: AR2
Pages: 307
Zydus Lifesciences Ltd
Annual Report
The report highlights Zydus Lifesciences Limited's transition from a conventional pharmaceutical company to an innovation-driven life sciences organization in FY22. Key achievements include the launch of Oxemia (Desidustat) in India and the emergency use approval of ZyCov-D, the world's first plasmid DNA vaccine for COVID-19. The company achieved net debt-free status, supported by the divestment of its India-centric animal health business. Additionally, the company expanded its digital footprint across manufacturing, supply chain, and R&D, while continuing its extensive CSR programs through the Zydus Medical College and Hospital in Dahod.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees